

Listing of Claims

1. (Canceled)

2. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises:

- a) residues 23-312 of the amino acid sequence set forth as SEQ ID NO: 11;
- b) an amino acid sequence at least 98% identical to the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11; or
- c) an immunogenic fragment comprising at least fifteen consecutive amino acids of the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11,

wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

3. (Currently amended) A substantially purified salivary *P. ariasi* polypeptide, wherein the polypeptide comprises an amino acid sequence at least 98% identical to the amino acid sequence as set forth as residues 23-312 of SEQ ID NO: 11, wherein administration of the polypeptide to a subject produces an immune response to *P. ariasi*.

4. (Currently amended) The *P. ariasi* polypeptide of claim 3, wherein the polypeptide comprises the an amino acid sequence set forth as at least 99% identical to residues 23-312 of SEQ ID NO: 11.

5. (Currently amended) An immunogenic fragment of the polypeptide of claim 4, wherein the immunogenic fragment comprises at least fifteen consecutive amino acids of the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.

6 - 24. (Canceled)

25. (Previously presented) An immunogenic composition comprising an effective amount of the polypeptide of claim 2 and a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Withdrawn) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising:

administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

28. (Withdrawn) The method of claim 27, wherein the immune response comprises a T cell response.

29. (Withdrawn) The method of claim 27, wherein the immune response comprises a B cell response.

30. (Withdrawn) The method of claim 27, wherein the subject comprises a non-human veterinary subject.

31. (Withdrawn) The method of claim 27, wherein the subject is a dog.

32. (Withdrawn) The method of claim 27, wherein the subject is a human.

33. (Withdrawn and currently amended) The method of claim 27, wherein the polypeptide comprises the amino acid sequence set forth as residues 23-312 of SEQ ID NO:11.

34. (Canceled)

35. (Withdrawn) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a

therapeutically effective amount of the *P. ariasi* polypeptide of claim 2, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

36. (Withdrawn and currently amended) The method of claim 35, wherein the polypeptide comprises the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.

37 - 79. (Canceled)

80. (Currently amended) The polypeptide of claim 4, wherein the polypeptide consists of comprises an amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.

81. (Previously presented) An immunogenic composition comprising an effective amount of the polypeptide of claim 3 and a pharmaceutically acceptable carrier.

82. (Withdrawn) A method for inducing an immune response to a *P. ariasi* polypeptide in a subject, comprising

administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inducing the immune response.

83. (Withdrawn) The method of claim 82, wherein the immune response comprises a T cell response.

84. (Withdrawn) The method of claim 82, wherein the immune response comprises a B cell response.

85. (Withdrawn) The method of claim 82, wherein the subject comprises a non-human veterinary subject.

86. (Withdrawn) The method of claim 82, wherein the subject is a dog.

87. (Withdrawn) The method of claim 82, wherein the subject is a human.

88. (Withdrawn) A method for inhibiting a symptom of a *Leishmania* infection or preventing a *Leishmania* infection in a subject, comprising administering to the subject a therapeutically effective amount of the *P. ariasi* polypeptide of claim 3, or a polynucleotide encoding the *P. ariasi* polypeptide, thereby inhibiting the symptom of the *Leishmania* infection or preventing the *Leishmania* infection.

89. (Withdrawn and currently amended) The method of claim 88, wherein the polypeptide comprises an amino acid sequence at least 99% identical to ~~the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.~~

90. (Withdrawn and currently amended) The method of claim 89, wherein the polypeptide comprises ~~the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.~~

91. (Withdrawn and currently amended) The method of claim 90, wherein the polypeptide ~~consists of~~comprises ~~the amino acid sequence set forth as~~ SEQ ID NO: 11.

92. (Withdrawn and currently amended) The method of claim 82, wherein the polypeptide comprises an amino acid sequence at least 99% identical to ~~the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.~~

93. (Withdrawn and currently amended) The method of claim 92, wherein the polypeptide comprises ~~the amino acid sequence set forth as~~residues 23-312 of SEQ ID NO: 11.

94. (Withdrawn and currently amended) The method of claim 93, wherein the polypeptide ~~consists of~~comprises ~~the amino acid sequence set forth as~~ SEQ ID NO: 11.

95. (Currently amended) The substantially purified salivary *P. ariasi* polypeptide of claim ~~380~~, wherein the polypeptide comprises ~~an amino acid sequence at least 99% identical to~~

the amino acid sequence set forth as SEQ ID NO: 11.

96. (Currently amended) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth as residues 23-312 of SEQ ID NO: 11.

97. (Currently amended) The substantially purified salivary *P. ariasi* polypeptide of claim 2, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 11.

98. (Canceled)